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Abstract—Adverse reaction caused by drugs is a potentially
dangerous problem which may lead to mortality and morbidity
in patients. Adverse Drug Event (ADE) extraction is a signifi-
cant problem in biomedical research. We model ADE extraction
as a Question-Answering problem and take inspiration from
Machine Reading Comprehension (MRC) literature, to design
our model. Our objective in designing such a model, is to exploit
the local linguistic context in clinical text and enable intra-
sequence interaction, in order to jointly learn to classify drug
and disease entities, and to extract adverse reactions caused by a
given drug. Our model makes use of a self-attention mechanism
to facilitate intra-sequence interaction in a text sequence. This
enables us to visualize and understand how the network makes
use of the local and wider context for classification.
I. INTRODUCTION
Adverse reactions caused by drugs is a potentially life-
threatening problem. Extracting such adverse effects is a non-
trivial problem. It has attracted the interest of researchers
and Health-care Providers. ADE (Adverse Drug Event) is
an umbrella term that includes adverse reaction to drugs,
unintended side effects and effects from discontinuation or
overdose of prescribed drugs. 94% of ADE cases are under-
reported by the official systems used in the pharmaceutical
industry [4]. It is reported that approximately 7000 deaths [5]
were caused by ADE annually, in a study conducted in 2000.
ADE are hard to discover because it manifests on certain
group of people in certain circumstances, and it may take
a long time to expose. Recent research in post-market drug
surveillance [4], [6], [7], [8] make use of informal text from
social media platforms like twitter. Our research is entirely
focused on biomedical text extracted from PubMed reports
[1].
The objective of ADE task is to identify drug and disease
mentions in a sequence and possible ADE relations between
them. Most of the prior work model this task as a entity and
relation extraction problem. There are two broad categories
of models used to solve this task. The first category uses
traditional pipeline method which consists of two steps
- Named Entity Recognition (NER) followed by relation
classification. Most early works [9], [10] in this area, use
pipeline models for ADE task. Pipeline models heavily rely
on manual feature engineering.
The second category of models are largely based on
End-to-End Deep Neural Networks (DNN). Recent advances
in deep learning have spawned diverse groups of neural
network architectures tailored for Computer Vision, Natural
Language Processing (NLP), Speech Recognition, etc,. The
promise of deep learning is automatic learning of significant
features from large data. The NLP community has adopted
Recurrent Neural Networks (RNN) for processing large,
unstructured, variable length text sequences. Miwa et al.,
[11] used Long Short Term Memory (LSTM) [20] based
RNNs for relation classification. Li et al., [13] used a feed
forward neural network to jointly extracting drug-disease
entity mentions and their ADE relations.
Li et al.’s work [3], which appears to be the state of
the art in ADE task, employs a neural joint model to
extract entities and their relations. They use a bidirectional
LSTM based RNN for learning entity representations
from text sequences. The output of this network is fed as
input to another bidirectional LSTM RNN, which learns
ADE representations. The LSTM parameters are shared by
both the networks. The ADE network processes Shortest
Dependency Paths (SDPs) between possible entities, based
on the dependency graph of the text sequence. Our approach
makes use of several techniques employed in [3].
In this work, we present a simple sequence model for the
combined task of Entity Recognition (ER) and Advese Drug
Event (ADE) extraction. The design of our model is inspired
by modern end-to-end sequence processing Recurrent Neural
Network architectures. It is considerably simple and easier
to train and extensible to similar tasks in NLP. The model
makes use of a self-attention mechanism to facilitate intra-
sequence interaction i.e., interaction between constituencies
of a sequence. We postulate that the attention mechanism,
widely employed by the deep learning community, could
be an apt replacement for SDP-based methods used in
[3], [11] and [14]. Additionally, we make use of the heat
maps generated by the attention mechanism, to visualize and
understand how the network makes use of the local linguistic
context and global semantic context, for entity recognition
and ADE extraction.
II. DATA
The data consists of annotated sentences extracted from
PubMed abstracts [1]. 6821 sentences contain at least one
ADE relation. 16695 unlabeled sentences with no ADE
(a) Sequence Length Histogram (b) Entity Count Histogram
Fig. 1. ADE corpus statistics
relations, are ignored. Each sample consists of an index and
a text sequence, followed by a drug entity from the sequence
and an ADE entity caused by the drug. We have modified
the data samples such that each sample is annotated with
one drug and a list of ADE’s caused by that drug. This
allows us to condition the model on a given drug and focus
on the segments of text corresponding to the effect of the
drug. As suggested in prior works [2], [3], 120 sentences
with overlapping entities (e.g., ”lithium intoxication”, where
”lithium” is a drug that causes ”lithium intoxication”) are
removed from the dataset. We present the sequence length
and average entity count in a sequence, as histograms in
figure 1.
III. PROBLEM DEFINITION
The problem we consider is two-fold. Given a sequence,
task one is to recognize drug and disease entities in the
sequence i.e., Entity Recognition. Task two is identifying
adverse drug events in the text sequence i.e., ADE Extraction.
Task one is a simple sequence labeling problem, where we
predict the category of each token in the sequence.
p(yentityi |Xseq) = f1(xi, Xseq) (1)
We have considered task two as a question answering
problem. In question answering, we are given (context,
query) tuples and tasked to select an answer from a vocabu-
lary. Most architectures in reading comprehension literature
construct a query-aware context representation for selecting
answers to query. Based on this idea, we considered ADE
extraction as a question answering problem, where the text
sequence becomes the context and the drug whose adverse
effects are to be predicted, becomes the query. Rather than
selecting an answer (adverse effect) from a vocabulary, we
consider each token in the sequence as a potential ADE.
We pose the question, ”Is the tth word in the sequence an
adverse effect of the given drug?”. Thus we have loosened
the constraints, to change a relation extraction problem, to a
sequential binary classification problem.
p(yADEi |Xseq, Xdrug) = f2(xi, Xseq, Xdrug) (2)
IV. MODEL DEFINITION
Our model can be partitioned into 4 stages - embedding,
encoding, interaction and prediction. We use pretrained word
TABLE I
ARCHITECTURE OF CHARCNN
Filter Attributes Values
Embedding Dimensions 25
Filter widths (w) [1,2,3,4,5,6]
Number of filter matrices [25.w]
embeddings to obtain distributed, continuous representation
of tokenized sequences. Character-level word representations
are obtained by using a combination of different sized convo-
lutional filters, similar to Kim et al.’s work [24]. The word-
level and character-level representations are concatenated and
fed as input to the encoder. The encoder is a bi-directional
LSTM, which processes the embedded sequence in either
directions. The forward and backward hidden states of the
LSTM are concatenated together to get an encoded sequence
{[
−→
hi ,
←−
hi ]}. We use the same encoder to obtain an encoded
representation of the drug. In the interaction stage, we iterate
through the timesteps of the sequence and obtain a weighted
representation of the whole encoded sequence, conditioned
on current state. We combine the weighted representation
with the current state to predict the entity type of the token
corresponding to current state. We apply an affine transfor-
mation to the combined representation and then combine it
with the encoded drug, to predict if the token corresponding
to current state is an ADE of the given drug. Each stage is
discussed in detail in the following sections.
A. Embedding
Distributed representation of words introduced by Bengio
et al., [15] has become competent a replacement for the
traditional bag-of-words encoding technique. Similar to [3],
we adopt multiple embedding matrices to represent different
representations of text sequence. Word-level and Character-
level representations of input sequence are obtained by tech-
niques explained in sections IV-A.1 and IV-A.2 respectively.
In addition to these, we make use of Parts of Speech (PoS)
and entity label information, by creating PoS embeddings
and label embeddings. Both of these embedding matrices
are randomly initialized.
1) Word Embedding: We use two instances of pretrained
word embeddings from PubMed word2vec [16]. We disable
gradient updates on the first instance - Fixed Embedding
(embf ) while we enable gradient updates on the second
instance - Variable Embedding (embv). Fixed embeddings
provide good, stable representations for drug and disease
entities in the sequence. Variable embeddings learn repre-
sentations for common words and phrases in the corpus that
highlight their role as linguistic supporting structures. We
concatenate the fixed and variable embeddings for word-level
representation of sequence tokens.
emb(x) = [embf(x); embv(x)] (3)
Fig. 2. Architecture of Character-aware Attentive ADENet
2) Character-level Embedding: Convolutional Neural
Networks (CNNs) have been shown to perform well on
NLP tasks. [24] and [25] have used CNNs for learning
character-level features in text. Kim et al., [24] propose a
character-aware neural language model, that learns character-
level word representations using CNNs - CharCNN. They
employ multiple convolutional filters of varying widths to
obtain feature vectors for words in the sequence. We follow
the same mechanism for character embedding.
Initially the text sequence is split into a nested sequence of
characters. A lookup of character embeddings is performed
and the vectors corresponding to individual characters in
a word, are stacked together to form a matrix. This is
followed by a series of convolutions with multiple filters
of different widths. Max-over-time pooling is applied to the
output of convolutional layer, to obtain character-level word
embeddings for each word in the sequence. The details of
filter size, number of filters and embedding size are tabulated
in Table I.
B. Encoder
The embedded text sequence which is comprised of word
embedding (fixed and variable), character embedding and
PoS feature embedding, is processed by the encoder, a
bidirectional LSTM based RNN. The forward {
−→
h i} and
backward {
←−
h i} hidden states of the RNN are concatenated
together. Now we have a primary representation of the text
sequence - the encoded sequence {hi}. The drug, in it’s
embedded form, is also processed by the same encoder
network. The final state of the RNN is considered the
encoded drug representation hdrug.
ht = [
−→
h t;
←−
h t] (4)
hdrug = [
−→
h drug;
←−
h drug] (5)
C. Interaction Layer
During each step t of encoder, information from the local
neighborhood flows from either directions. The hidden state
h¯t represents the local context corresponding to t
th time
step. In [3], ADE relation extraction is done by building
SDPs between drug entities and potential ADE candidates
in the sequence. We have designed the interaction layer as
an alternative to this approach. The objective is to facilitate
interaction between different parts of the sequence. Our
model considers each token in the sequence as a potential
entity and an ADE candidate.
In the interaction stage, we iterate through the encoded
sequence and learn a entity representation and an ADE
representation for each sequence. During each time step t, the
model creates a weighted representation over all the encoded
states {h¯i}, conditioned on the current state ht. We choose
multiplicative attention mechanism proposed in [22], over
additive attention [21], since the former is faster and more
space-efficient [23].
h¯i =
∑
j
aijhj (6)
ai = softmax(fatt(hi, hj)) (7)
fatt(hi, hj) = h
T
i Wahj (8)
D. Prediction
At each step t of the interaction layer, we construct entity
and ADE representations corresponding to token t. For entity
representation, we consider the embedding of predicted label
of the previous token, lt−1. We concatenate previous label
embedding lt−1 with weighted representation of encoded
sequence h¯t and the current state ht. This gives us the
entity representation [lt−1; h¯t;ht]. A tanh non-linearity is
applied, followed by an affine transformation. The output of
this operation is normalized with softmax, which provides a
probability distribution over the entity labels.
p(yentt |Xseq) = softmax(tanh(W
entrent + bent)) (9)
rent = [lt−1; h¯t;ht] (10)
We apply an affine transformation over rent to get r¯ent
to enable variation between entity and ADE representation.
We concatenate encoded drug state hdrug with r¯
ent and
the embedding of label predicted at current step lt, to
obtain the ADE representation, rade. By applying another
affine transformation over rade, followed by softmax, we
get the probability distribution over ADE labels, 0 or 1
corresponding to not an ADE and ADE.
p(yadet |Xseq, Xdrug) = softmax(W
aderade + bade) (11)
rade = [hdrug; r¯
ent; lt] (12)
r¯ent = W crent + bc (13)
lt = embl(yˆt) (14)
yˆt = argmax(p(y
ent
t |Xseq)) (15)
TABLE II
COMPARISON WITH THE STATE OF THE ART
Model
Entity Recognition ADE Extraction
P R F1 P R F1
Li [3] 82.70 86.70 84.60 67.50 75.80 71.40
Our Model 88.41 82.41 85.30 86.28 87.29 86.78
V. MODEL VARIANTS AND FEATURES
We have experimented with different variants of the
model architecture presented in figure 2. The performance
of these models are tabulated in Table III. We started
with a baseline model - ADENet, which consists of an
LSTM-based bidirectional encoder. The final state of
encoder which processes the drug, is taken as encoded drug
representation. At each step of encoding the sequence, the
hidden state h¯t is combined with the embedding of entity
label yˆ
entity
t−1 predicted in the previous step. This becomes
the entity representation corresponding to token X
seq
t . An
affine transformation, followed by a tanh non-linearity
gives the logits for entity classification. By combining the
current hidden state h¯t with label embedding of current
entity prediction yˆ
entity
t and the encoded drug h¯
drug, we
obtain the ADE representation of X
seq
t . Likelihood of ADE
is obtained by applying softmax over affine transformed
ADE representation.
Parts of speech tags of the text sequence are obtained
using nltk’s [17] PoS tagger. PoS embeddings of the
sequence are concatenated with the word embeddings to
get a richer primary sequence representation. This model
- Baseline + PoS Features outperforms the baseline by a
small margin.
The Interaction layer, defined in section IV-C, is added
to the baseline - Baseline + Attention. We can observe a
sharp increase in the performance of this model, in both
the tasks, compared to the baseline. This is due to the fact
that during each step of prediction, the model has access
to the encoded representation of the whole sequence. By
conditioning the weighted representation on the current state,
the model performs a search on the sequence, looking for
information relevant to current prediction. The hidden state
bottleneck [21] is overcome by allowing the model to peek
at the whole sequence.
When PoS features are added to this model - Baseline +
Attention + PoS Features, there is an increase in performance
on both the tasks. We theorize that the attention mechanism
learns to make better use of new information provided by
the additional features (PoS). This theory holds true when
we add character embeddings to the model.
We then introduce character embedding as an additional
feature to the model - Baseline + Attention + Character
Embedding. This results in a much better performance. The
character embeddings contain rich morphological informa-
tion, which are crucial in differentiating a drug or disease
TABLE III
PERFORMANCE COMPARISON OF MODEL AUGMENTED WITH VARIOUS FEATURES
Model
Entity Recognition ADE Extraction
P R F1 P R F1
Baseline 79.91 67.62 72.25 75.30 80.27 77.70
Baseline + PoS Features 79.93 68.73 73.90 76.76 81.14 78.89
Baseline + Attention 83.57 74.29 78.65 81.14 81.49 81.31
Baseline + Attention + PoS Features 84.23 75.35 79.53 81.93 83.14 82.53
Baseline + Attention + Character Embedding 82.69 77.74 80.13 79.35 86.20 82.62
Baseline + Attention + Character Embedding + PoS Features 88.41 82.41 85.30 86.28 87.29 86.78
(a) ER F1 Scores (b) ER F1 Scores < 90.
(c) ADE F1 Scores (d) ADE F1 Scores < 90.
Fig. 3. Histogram of F1 scores in Entity Recognition and ADE Extraction
tasks are presented in figures (a) and (c) respectively. (b) and (d) ignore F1
scores greater than 90.
entity from a regular English word.
And finally when we add PoS features to this model -
Baseline + Attention + Character Embedding + PoS Fea-
tures, we obtain our best performing model by far (illustrated
in figure 2). Based on these observations, we add that by
including domain-specific or context-specific features and
facilitating interaction between the features corresponding to
individual tokens in the sequence, the performance on NLP
tasks could be significantly improved.
VI. TRAINING
We train our models with an initial learning rate of 0.001
and a batch size of 16, with Adagrad Optimizer [18]. We
have split the dataset in 8:1:1 ratio into training set, test
set and validation set. We use a dropout [19] of 0.5 for the
LSTM encoder. All the trainable parameters of the model are
initialized with a random uniform initializer within range (-
0.01, 0.01). All our models converge within 10 epochs. The
dimensions of pretrained PubMed word embeddings is 200.
Dimensions of character embedding, PoS embedding and
label embedding, along with the rest of the hyperparameter
settings, are listed in Table IV.
Fig. 4. Correlation between F1 scores of ER task and ADE task
TABLE IV
HYPERPARAMETER SETTINGS
Hyperparameter Value
Word Embedding 400
Character Embedding 525
PoS Embedding 25
Label Embedding 25
BiLSTM hidden dimensions [150, 150]
Learning rate 0.01
VII. EXPERIMENT RESULTS
Table II compares the performance of our best performing
model with that of Li et al.’s state of the art model [3]. Our
model’s performance in Entity Recognition is slightly higher
compared to the state of the art. We also present the results
of our ADE extraction system. It is unfair to compare it’s
performance with that of [3], as ADE extraction is treated
as a relation extraction problem in the latter. Although, in
a practical setting, we could augment an end-to-end neural
network with a drug lexicon, to condition the model to extract
ADE’s caused by a specific drug. By constraining our model
to focus on ADE’s only relevant to a particular drug, we have
achieved an F1 score of 86.78, which is an improvement of
approximately 15% over the state of the art.
VIII. ANALYSIS
Our analysis is focused on predictions made by our best
performing model which includes Character Embedding, PoS
features and Attention mechanism. We have clustered the
Fig. 5. Visualization of Attention scores. To understand the figure, the sequence on the left should be read from top to bottom. Every row is a
probability distribution (normalized attention score) across the whole sequence conditioned on the token on the left. Notice the peak in attention in
positions corresponding to drug or disease entities.
data samples into three categories based on our model’s
performance on the sample. We studied the properties of
each category of samples and present our observations in this
section. The histograms of F1 scores of Entity Recognition
and ADE extraction tasks are presented in figure 3.
We can clearly observe that more than 60% of samples
achieve an F1 score greater than 95 in ADE extraction task
and almost 50% of samples achieve an F1 score greater than
95 in Entity Recognition task. Figures 3(b) and 3(d) provide
a closer look at the rest of the samples. The performance of
the rest of the samples seem to be almost evenly distributed
between scores of 20 and 90, with a few outliers. We can
also notice a sharp peak around the score of zero.
We further investigate these samples by studying the effect
of text sequence length, number of entities in the sequence
and number of ADEs in the sequence, on performance.
Based on which we conclude that there is no observable
correlation between sequence length and performance. A
similar comparison based on number of entities and number
of drugs in the sequence, does not reveal any significant
distinguishing features that separate good samples from
bad samples. We then, compare the performance of our
model in individual tasks. It is clear from figure 4 that there
is an increase in ADE performance with increase in ER
performance. This kind of correlation is to be expected in a
joint model, where sub-systems designed to solve different
problems share parameters.
As discussed in section IV-C, we employ an attention
mechanism across all the encoded states, corresponding to
word tokens in the text sequences. This mechanism allows
the system at each prediction step, to focus on information
from the sequence relevant to current prediction. We have
mapped the attention scores ai obtained from equation 7,
to the tokens in the text sequence and present a sample
visualization of the interaction layer in figure 5. We can
observe clear peaks in attention scores, corresponding to drug
and disease entities. This pattern is observed in every good
sample (high performance in both the tasks) from the test
set. To add to that, in most bad samples, the attention seems
to be scattered across the tokens in the sequence. This could
be interpreted as the model searching the encoder states, for
information that could be useful for prediction and failing to
find it.
IX. CONCLUSION
In this paper, we propose a joint model for Entity Recog-
nition and Adverse Drug Event extraction in biomedical text.
By loosening the constraints on ADE extraction, our model
outperforms the state of the art by a large margin. The
performance of our Entity Recognition sub-system is slightly
better than that of state of the art. We observe that by using an
attention mechanism to facilitate intra-sequence interaction,
we could replace SDP based methods used in prior work.
Additionally, the use of attention mechanism allows us to
investigate the dependence of classifier on different segments
of the text sequence.
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